Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Boehringer Ingelheim
Moodys
Express Scripts
Baxter

Last Updated: March 20, 2023

Ridgeback Biotherapeutics Company Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Ridgeback Biotherapeutics
Patents:0
Tradenames:1
Ingredients:1
BLAs:1

Biologic Drugs for Ridgeback Biotherapeutics

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Patent Expiration
Ridgeback Biotherapeutics EBANGA ansuvimab-zykl For Injection 761172 2020-12-21 See Plans and Pricing
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Mallinckrodt
Express Scripts
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.